Nature Reviews - Cardiology
AUGUST 6, 2024
Nature Reviews Cardiology, Published online: 07 August 2024; doi:10.1038/s41569-024-01064-4 In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical trials.
HCPLive
AUGUST 6, 2024
A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.
Science Daily - Heart Disease
AUGUST 6, 2024
Doctors recommend making fruits and vegetables a foundational part of the treatment of patients with hypertension. Diets high in fruits and vegetables are found to lower blood pressure, reduce cardiovascular risk, and improve kidney health due to their base-producing effects. A new study details the findings from a five-year interventional randomized control trial.
HCPLive
AUGUST 6, 2024
In an interview with HCPLive, Angela Moreland, MD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.
Med Page Today
AUGUST 6, 2024
(MedPage Today) -- Poor physical function appeared to be the primary reason for increased fracture risk in older women with type 2 diabetes, a prospective observational study suggested. According to Mattias Lorentzon, MD, PhD, of Sahlgrenska University.
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included. Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
HCPLive
AUGUST 6, 2024
Noureddin reviews key considerations for starting, monitoring, and discontinuing treatment with resmetirom in patients with noncirrhotic MASH.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
AUGUST 6, 2024
Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.
JAMA Cardiology
AUGUST 6, 2024
This secondary analysis of the Valsartan in Acute Myocardial Infarction (VALIANT) and Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) randomized clinical trials investigates the changes over time in sudden death rate after myocardial infarction and the characteristics of people dying suddenly.
HCPLive
AUGUST 6, 2024
The most commonly reported symptoms were bodily pain, joint tenderness and swelling, and joint pain.
American College of Cardiology
AUGUST 6, 2024
What is the degree to which patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF) are eligible for quadruple medical therapy, and what are the projected benefits of in-hospital initiation?
HCPLive
AUGUST 6, 2024
Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.
American College of Cardiology
AUGUST 6, 2024
The following are key points to remember from a state-of-the-art guide to transcatheter aortic valve (TAV) design and systematic planning for a redo-TAV (TAV-in-TAV) procedure.
Cardiovascular Diabetology
AUGUST 6, 2024
The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This st.
HCPLive
AUGUST 6, 2024
The repository corticotropin injection is designed to help patients manage their medication alongside a range of chronic and acute autoimmune and inflammatory conditions.
JAMA Cardiology
AUGUST 6, 2024
This randomized clinical trial investigates the optimal antithrombic therapy after percutaneous left atrial appendage occlusion (LAAO).
Science Daily - Heart Disease
AUGUST 6, 2024
Researchers have developed a new compound, ZTA-261, that binds to thyroid hormone receptor beta (THR ). THR plays an important role in the regulation of lipid metabolism, which affects lipid levels in the blood. Mice administered the drug showed decreased lipid levels in the liver and blood, with fewer side effects in the liver, heart, and bones compared to existing compounds.
HCPLive
AUGUST 6, 2024
These data from the United Arab Emirates provide insight into the comorbidities, epidemiology, patterns of treatment, and use of healthcare resources of alopecia areata patients.
Cardiovascular Diabetology
AUGUST 6, 2024
Gestational diabetes mellitus (GDM) significantly impacts maternal and infant health both immediately and over the long term, yet effective early diagnostic biomarkers are currently lacking. Thus, it is essent.
Nature Reviews - Cardiology
AUGUST 6, 2024
Nature Reviews Cardiology, Published online: 07 August 2024; doi:10.1038/s41569-024-01069-z Acute ischaemic stroke induces persistent innate immune memory through epigenetic changes in myeloid progenitors in the bone marrow, and this innate immune training contributes to cardiac remodelling and dysfunction in the long term, according to a new study.
Cardiovascular Diabetology
AUGUST 6, 2024
Atrial fibrillation (AF) is acknowledged as a disease continuum. Despite catheter ablation being recommended as a primary therapy for AF, the high recurrence rates have tempered the initial enthusiasm. Insulin.
HCPLive
AUGUST 6, 2024
Gastroenterologist experts discuss the current landscape of biologic treatments for inflammatory bowel disease and the occasional necessity to switch between different biologic agents, while also sharing insights on their preferred treatment sequencing strategies.
Frontiers in Cardiovascular Medicine
AUGUST 6, 2024
AimsHistorically, atherosclerotic cardiovascular disease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). In this narrative review we explore the residual ASCVD risk profile beyond LDL-C with a focus on hypertriglyceridaemia, recent clinical trials of therapeutics targeting hypertriglyceridaemia and novel modalities addressing other residual ASCVD risk factors.FindingsHypertriglyceridaemia remains a significant ASCVD risk despite low LDL
HCPLive
AUGUST 6, 2024
Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management.
Frontiers in Cardiovascular Medicine
AUGUST 6, 2024
Myocardial infarction (MI) stands at top global causes of death in developed countries, owing mostly to atherosclerotic plaque growth and endothelial injury-induced reduction in coronary blood flow. While early reperfusion techniques have improved outcomes, long-term treatment continues to be difficult. The function of lncRNAs extends to regulating gene expression in various conditions, both physiological and pathological, such as cardiovascular diseases.
Learning + Leading
AUGUST 6, 2024
Often when people visit their local pharmacy, they assume that all the person behind the counter does is dispense medications. While that’s certainly a vital part of the job, the pharmacy technician’s responsibilities extend far beyond filling prescriptions, especially in recent years.
Becker's Hospital Review - Cardiology
AUGUST 6, 2024
The rate of cardiology follow-up visits has increased, though racial disparities still exist, according to a study published Aug. 6 in The Annals of Internal Medicine.
HCPLive
AUGUST 6, 2024
This research compared the efficacy among a cohort of individuals with obesity to the general population of adult patients with eczema.
The British Journal of Cardiology
AUGUST 6, 2024
In recent years, artificial intelligence (AI) has been used to improve the precision of valvular heart disease diagnosis and treatment. It has the ability to identify and risk stratify patients with valvular heart disease and holds promise in improving the innovation of new treatments through shorter, safer and more effective clinical trials. AI can help to guide the treatment of patients with valvular heart disease, by aiding in optimal device selection for transcatheter valvular interventions
HCPLive
AUGUST 6, 2024
The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.
The British Journal of Cardiology
AUGUST 6, 2024
Training and development of cardiology trainees in the UK at a local level, is usually delivered through senior supervision by a consultant cardiologist. This training is overseen by clinical and educational supervisors, whose role is to set goals in line with existing training curricula. This is crucial to ensuring trainee development and attainment of skills in line with a pre-determined ‘gold standard’ for independent practice.
American College of Cardiology
AUGUST 6, 2024
In this interview, Maria EmÃÂlia Figueiredo Teixeira, MD, PhD and Sidney C. Smith Jr., MD, MACC discuss the primary findings uncovered by the Feel Trial.
The British Journal of Cardiology
AUGUST 6, 2024
Atrial fibrillation (AF) is responsible for significant patient morbidity, and obesity is a major contributor to AF incidence and symptom burden. Weight loss has been shown to positively modify AF symptoms, but weight loss in a real-world population is often only temporary. This randomised study set out to examine if smartphone-based app technology could increase weight loss in a patient population with obesity and AF.
HCPLive
AUGUST 6, 2024
Pneumonia misdiagnoses are common, with one-third of pneumonia diagnoses changing from hospital admission to discharge, a study found.
Journal of Cardiovascular Pharmacology
AUGUST 6, 2024
Patients undergoing anthracycline-based cancer treatments have an increased risk of heart failure (HF) and adverse metabolic outcomes such as malnutrition and cachexia. This retrospective study explored the impact of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on these outcomes in HF patients previously treated with anthracyclines. Using the TriNetx research network, we identified 1,545 patients with a history of SGLT2i use and 17,681 without.
HeartRhythm
AUGUST 6, 2024
Cardiac sarcoidosis (CS) manifestations, often related to rhythm abnormalities and ventricular dysfunction, are non-specific and can mimic other cardiomyopathies.1 Establishing the diagnosis of CS can be challenging and requires histologic confirmation from affected myocardium (or an extracardiac site, combined with imaging features of cardiac involvement).
Journal of Cardiovascular Pharmacology
AUGUST 6, 2024
Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload. Additional agents can be utilized for augmentation but there is limited guidance on agent selection. The study objective was to determine if chlorothiazide or metolazone is associated with differences in diuretic efficacy or safety in loop diuretic-resistant patients with AHF and renal dysfunction.
Expert insights. Personalized for you.
124 
Let's personalize your content